{
    "2019-04-01": [
        [
            {
                "time": "2018-07-09",
                "original_text": "Novartis (NVS) to Acquire Subsidiary of IFM Therapeutics",
                "features": {
                    "keywords": [
                        "Novartis",
                        "acquire",
                        "IFM Therapeutics",
                        "subsidiary"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-07-09",
                "original_text": "Novartis Snags A $1.6 Billion Buy That Could Rival These Biotechs",
                "features": {
                    "keywords": [
                        "Novartis",
                        "1.6 billion",
                        "buy",
                        "biotechs"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-07-09",
                "original_text": "Novartis Announces $1.575B Acquisition Of IFM Tre",
                "features": {
                    "keywords": [
                        "Novartis",
                        "1.575B",
                        "acquisition",
                        "IFM Tre"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-07-09",
                "original_text": "Swiss drugmaker Novartis must face doctor kickback suit, U.S. judge rules",
                "features": {
                    "keywords": [
                        "Novartis",
                        "kickback",
                        "suit",
                        "judge"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-07-09",
                "original_text": "BMOâ€™s Got A Point About Teva Stock, But Are Investors Willing To Listen?",
                "features": {
                    "keywords": [
                        "BMO",
                        "Teva",
                        "stock",
                        "investors"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-07-09",
                "original_text": "Novartis to pay $310 million for assets from inflammation specialist IFM",
                "features": {
                    "keywords": [
                        "Novartis",
                        "310 million",
                        "assets",
                        "inflammation",
                        "IFM"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-07-09",
                "original_text": "Novartis scoops up IFM immunotherapy subsidiary for $310 million",
                "features": {
                    "keywords": [
                        "Novartis",
                        "immunotherapy",
                        "subsidiary",
                        "310 million"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}